Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last ¥2,365 JPY
Change Today +30.00 / 1.28%
Volume 2.1M
As of 2:00 AM 05/25/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

3-5-1, Nihonbashi-honcho

Chuo-ku

Tokyo, 103-8426

Japan

Phone: 81 3 6225 1111

Fax:

Daiichi Sankyo Company, Limited engages in the research, development, manufacture, import, sale, and marketing of pharmaceutical products. The company operates in Japan, North America, Europe, and India. The company’s products primarily include Olmesartan, an antihypertensive agent, which is marketed as Olmetec in Japan and Europe, as Benicar in the Unites States, and as Olvance in India; Levofloxacin, a synthetic antibacterial agent that is marketed as Cravit in Japan and other Asian countries; and Pravastatin, an antihyperlipidemic agent, which is marketed as Mevalotin in Japan, and other Asian and European countries. The company offers Calblock and Artist, which are antihypertensive products; Loxonin, an anti-inflammatory analgesic; Omnipaque, a contrast agent; Kremezin for the treatment of chronic renal failure; Urief for treating dysuria; and Sunrythm, an antiarrhythmic agent. It also offers Venofer for the treatment of iron deficiency anemia; and WelChol, an antihyperlipidemic agent for the treatment of diabetes. The company’s product candidates under clinical development pipeline focusing on the treatment of cardiovascular diseases, malignant neoplasm, glucose metabolic disorders, infectious diseases, immunological allergic diseases, and bone/joint diseases. The company manufactures and sells OTC drugs, cosmetics, medical equipments, food and beverage products, and agrochemicals and chemicals; manufacture of active pharmaceutical ingredients and intermediates, veterinary medicines, and raw materials for pharmaceuticals; and provision of agency services. History Daiichi Sankyo Company, Limited was founded in 1899.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4568:JP ¥2,365.00 JPY +30.00

4568 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Array BioPharma Inc $7.52 USD +0.14
BioCryst Pharmaceuticals Inc $11.42 USD +0.12
BioMerieux €103.75 EUR +4.08
Infinity Pharmaceuticals Inc $12.85 USD -0.02
Ipsen SA €51.16 EUR +0.13
View Industry Companies
 

Industry Analysis

4568

Industry Average

Valuation 4568 Industry Range
Price/Earnings 34.8x
Price/Sales 1.8x
Price/Book 1.2x
Price/Cash Flow 5.1x
TEV/Sales 1.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DAIICHI SANKYO CO LTD, please visit www.daiichisankyo.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.